Recently, the internationally renowned consulting firm Citeline released the "Pharma R&D Annual Review 2026" and introduced a new, more precise analytical method to select the "Top 25 Global Pharmaceutical Companies by Pipeline Scale".

On March 26, Sino Biopharm (1177.HK) released its 2025 annual results. Driven by the in-depth advancement of its comprehensive innovation and development strategy and the rapid volume growth of innovative products launched intensively over the past three years, the company has delivered impressive results of double-digit growth in both revenue and net profit for four consecutive reporting periods.

On March 23, MSCI (Morgan Stanley Capital International), an internationally authoritative index provider, released its latest Environmental, Social, and Governance (ESG) rating results.

On March 22, the China Development Forum 2026 Annual Conference opened in Beijing. Qiang Li, a member of the Standing Committee of the Political Bureau of the CPC Central Committee and Premier of the State Council, attended the opening ceremony and delivered a keynote speech.